One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Shivaji Dasgupta, an autonomous Brand Consultant, writes that India’s obsession with shortcuts risks turning a breakthrough ...

Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of key drugs, Mounjaro, Zepbound, Jardiance, and Taltz beat ...

while another link invites visitors to “learn more” about Mounjaro. In a further play on the musical theme of the campaign, Lilly has teamed up with iHeartRadio to get the word out.

Eli Lilly has filed lawsuits against four telehealth companies it says are selling compounded versions of Mounjaro, Lilly’s diabetes drug, and Zepbound, a drug for weight loss and control.

Eli Lilly LLY2.48%increase; green up pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net ...